Company Profile
HLS Therapeutics Inc., a specialty pharmaceutical company acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease globally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia.
Its portfolio also includes CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril, Nilemdo, a bempedoic acid product for cardiovascular risk reduction, Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction, and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease.
It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs
Including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels.
Additionally, it holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. The company serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.